<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vet Sci</journal-id><journal-id journal-id-type="iso-abbrev">Vet Sci</journal-id><journal-id journal-id-type="publisher-id">vetsci</journal-id><journal-title-group><journal-title>Veterinary Sciences</journal-title></journal-title-group><issn pub-type="epub">2306-7381</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40005942</article-id><article-id pub-id-type="pmc">PMC11860592</article-id><article-id pub-id-type="doi">10.3390/vetsci12020181</article-id><article-id pub-id-type="publisher-id">vetsci-12-00181</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Utilizing NF-&#x003ba;B Signaling in Porcine Epithelial Cells to Identify a Plant-Based Additive for the Development of a Porcine Epidemic Diarrhea Virus Vaccine</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-9675-5437</contrib-id><name><surname>Hoa</surname><given-names>Nguyen-Thanh</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Formal analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-vetsci-12-00181" ref-type="aff">1</xref><xref rid="af2-vetsci-12-00181" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-5256-3265</contrib-id><name><surname>Afzal</surname><given-names>Haroon</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="af1-vetsci-12-00181" ref-type="aff">1</xref></contrib><contrib contrib-type="author"><name><surname>Doan</surname><given-names>Thu-Dung</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><xref rid="af1-vetsci-12-00181" ref-type="aff">1</xref><xref rid="af3-vetsci-12-00181" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Murtaza</surname><given-names>Asad</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="af4-vetsci-12-00181" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Yen</surname><given-names>Chia-Hung</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af5-vetsci-12-00181" ref-type="aff">5</xref><xref rid="c1-vetsci-12-00181" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0009-0006-0610-2843</contrib-id><name><surname>Chung</surname><given-names>Yao-Chi</given-names></name><xref rid="af3-vetsci-12-00181" ref-type="aff">3</xref><xref rid="c1-vetsci-12-00181" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Jung</surname><given-names>Kwonil</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vetsci-12-00181"><label>1</label>International Program in Animal Vaccine Technology, National Pingtung University Science and Technology, Pingtung 91201, Taiwan</aff><aff id="af2-vetsci-12-00181"><label>2</label>Department of Virology, National Institute of Veterinary Research NIVR, Hanoi 11500, Vietnam</aff><aff id="af3-vetsci-12-00181"><label>3</label>Graduate Institute of Animal Vaccine Technology, College of Veterinary Medicine, National Pingtung University of Science and Technology, Pingtung 91201, Taiwan</aff><aff id="af4-vetsci-12-00181"><label>4</label>Faculty of Biosciences, Fisheries and Economics, Norwegian College of Fishery Science, UiT&#x02014;The Arctic University of Norway, P.O. Box 6050 Troms&#x000f8;, Norway</aff><aff id="af5-vetsci-12-00181"><label>5</label>Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung 807378, Taiwan</aff><author-notes><corresp id="c1-vetsci-12-00181"><label>*</label>Correspondence: <email>chyen@kmu.edu.tw</email> (C.-H.Y.); <email>ycchung@mail.npust.edu.tw</email> (Y.-C.C.)</corresp></author-notes><pub-date pub-type="epub"><day>18</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>12</volume><issue>2</issue><elocation-id>181</elocation-id><history><date date-type="received"><day>13</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>10</day><month>2</month><year>2025</year></date><date date-type="accepted"><day>15</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract abstract-type="plain-language-summary"><title>Simple Summary</title><p>A porcine epithelial NF-&#x003ba;B reporter cell line was created to identify plant extracts that activate the NF-&#x003ba;B signaling pathway. Among the 224 screened extracts, 3 showed an increase in NF-&#x003ba;B activity and were further assessed for their potential application as additives in PEDV vaccines. Toxicity assessments, both in vitro and in vivo, were performed, resulting in the selection of chamomile as a candidate for an in vivo vaccination study. Mice received inactivated PEDV vaccinations, formulated with a commercial adjuvant and with or without the addition of chamomile, via oral and intramuscular (I.M.) routes. Vaccine efficacy was determined by measuring virus-specific IgG and IgA antibodies. Chamomile did not affect the I.M. vaccination but showed a propensity to elevate antibody titers for the oral vaccination. These results indicate that chamomile extract is worthy of more study as a potential ingredient in PEDV vaccines. This study underscores the potential of PK15-KBR cells in identifying potential mucosal adjuvants and positions chamomile extract as a valuable candidate for enhancing the creation of effective vaccines for PEDV alongside potential other viral diseases in animals.</p></abstract><abstract><title>Abstract</title><p>The nuclear factor-kappa B (NF-&#x003ba;B) signaling pathway plays a crucial role in regulating immune responses in epithelial cells. In this study, we established a porcine epithelial NF-&#x003ba;B reporter cell line (PK15-KBR) as an in vitro platform to screen plant-based extracts for their potential use as vaccine adjuvants against porcine epidemic diarrhea virus (PEDV). The NF-&#x003ba;B inducers were further tested for toxicity assessments, either using CCK-8 assays or intramuscular injection in mice, finally followed by vaccination studies to evaluate their adjuvancy. Initial experiments confirmed that TNF-&#x003b1; effectively activated NF-&#x003ba;B signaling in PK15-KBR cells in a dose-dependent manner, validating the platform&#x02019;s reliability at Z&#x02019; value of 0.68. Of the 224 testers, 3 candidates, including chamomile, mulberry and <italic toggle="yes">Boerhaavia diffusa</italic>, showed induction activity; however, only chamomile induced a dose-dependent response in PK15-KBR cells. As a proof of concept, chamomile, used as an adjuvant in oral vaccination, demonstrated significantly higher IgG levels at an early stage (day 14, <italic toggle="yes">p</italic> &#x0003c; 0.05) and enhanced IgA titers. These findings highlight the use of the PK15-KBR cell line in identifying mucosal adjuvants and position chamomile extract as a promising candidate for enhancing vaccine-induced immunity.</p></abstract><kwd-group><kwd>NF-&#x003ba;B signaling pathway</kwd><kwd>porcine epidemic diarrhea virus (PEDV)</kwd><kwd>epithelial cells</kwd><kwd>PK15-KBR cell line</kwd><kwd>plant extracts</kwd><kwd>in vitro tool</kwd><kwd>mucosal immunity</kwd></kwd-group><funding-group><award-group><funding-source>Taiwan National Science and Technology Council</funding-source><award-id>NSTC 112-2637-B-020-010-</award-id><award-id>113-2637-B-020-006-</award-id><award-id>113-2320-B-037-018</award-id><award-id>NSTC 113-2622-8-037-002-TB</award-id></award-group><award-group><funding-source>Kaohsiung Medical University</funding-source><award-id>KMU-TC113A03-1</award-id><award-id>KMUTC113A04</award-id></award-group><funding-statement>This study was partially supported by grants from the Taiwan National Science and Technology Council (NSTC 112-2637-B-020-010-, 113-2637-B-020-006-, 113-2320-B-037-018 and NSTC 113-2622-8-037-002-TB) and Kaohsiung Medical University (KMU-TC113A03-1 and KMUTC113A04).</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vetsci-12-00181"><title>1. Introduction</title><p>NF-&#x003ba;B plays a crucial role in maintaining immune homeostasis and regulating inflammation in epithelial tissues, which are primary targets for enteric viruses [<xref rid="B1-vetsci-12-00181" ref-type="bibr">1</xref>]. One significant pathogen affecting these tissues is the porcine epidemic diarrhea virus (PEDV), which is responsible for severe watery diarrhea and high mortality rates in neonatal piglets, making it a major cause of diarrhea outbreaks on pig farms worldwide [<xref rid="B2-vetsci-12-00181" ref-type="bibr">2</xref>]. Epithelial cells serve as the first line of defense against such infections by establishing a protective monolayer, secreting chemical barriers, and activating immune processes. These activities are integral to the innate immune system&#x02019;s role in protecting the mucosal barrier [<xref rid="B3-vetsci-12-00181" ref-type="bibr">3</xref>]. Upon detecting pathogens like PEDV, NF-&#x003ba;B is activated, and multiple aspects of immune response are triggered through the production of antimicrobial peptides (AMPs) and other effector molecules [<xref rid="B4-vetsci-12-00181" ref-type="bibr">4</xref>]. This mechanism is essential for an effective immune response and maintaining the integrity of epithelial barriers.</p><p>Several plant extracts have been shown to significantly modulate NF-&#x003ba;B signaling pathways in epithelial cells, highlighting their potential therapeutic roles in managing inflammation and related diseases [<xref rid="B5-vetsci-12-00181" ref-type="bibr">5</xref>,<xref rid="B6-vetsci-12-00181" ref-type="bibr">6</xref>]. They hold great potential as vaccine adjuvants due to their safety, long-lasting immunity, dosage sparing, and economic benefits [<xref rid="B7-vetsci-12-00181" ref-type="bibr">7</xref>]. Additionally, oral administration of plant-derived adjuvants has been shown to reduce the duration of clinical symptoms, decrease mortality risks, and improve overall outcomes compared to control treatments [<xref rid="B8-vetsci-12-00181" ref-type="bibr">8</xref>].</p><p>Unlike in vivo experiments, cell-based assays provide more direct, verified, and high-throughput platforms for screening novel adjuvants [<xref rid="B9-vetsci-12-00181" ref-type="bibr">9</xref>]. This approach allows for evaluating a large library of plant extracts and isolates to discover novel modulators of NF-&#x003ba;B activity. Although the adjuvant activities have been successfully investigated in immune cells, there are limitations in evaluating these plant products on epithelial cells [<xref rid="B10-vetsci-12-00181" ref-type="bibr">10</xref>,<xref rid="B11-vetsci-12-00181" ref-type="bibr">11</xref>]. Given their importance, epithelial cells represent promising in vitro systems for identifying new mucosal adjuvants derived from natural products, such as plant extracts.</p><p>Despite the use of NF-&#x003ba;B reporter cells to evaluate immunomodulatory products, most platforms rely on immune cells, such as T cells [<xref rid="B12-vetsci-12-00181" ref-type="bibr">12</xref>] and B cells [<xref rid="B13-vetsci-12-00181" ref-type="bibr">13</xref>], or antigen-presenting cells, including macrophages [<xref rid="B14-vetsci-12-00181" ref-type="bibr">14</xref>] and dendritic cells [<xref rid="B10-vetsci-12-00181" ref-type="bibr">10</xref>]. The source of the cell lines used in these assays is important, as porcine-derived epithelial cell lines can offer a more accurate model for assessing the innate responses in pigs. Previous research has focused on viral or bacterial stimuli, such as transmissible gastroenteritis virus (TGEV) and <italic toggle="yes">Haemophilus parasuis</italic>, to study NF-&#x01d0b;B signaling in PK-15 cells [<xref rid="B15-vetsci-12-00181" ref-type="bibr">15</xref>,<xref rid="B16-vetsci-12-00181" ref-type="bibr">16</xref>]. The impact of plant-derived adjuvants on NF-&#x003ba;B signaling in PK-15 cells highlights a critical gap in the research.</p><p>To address this gap, we developed a stable NF-&#x003ba;B-luciferase cell line derived from the PK-15 porcine cells, referred to as PK15-KBR. This cell line maintained stability for at least ten passages in culture, retaining robust reporter gene expression. Upon stimulation with TNF-&#x003b1;, PK15-KBR exhibited clear NF-&#x003ba;B activation, as confirmed by luciferase assays. The platform was further tested on a 96-well plate, indicating its suitability for high-throughput screening. Using this system, we conducted a preliminary screening of crude plant extracts, followed by toxicity assessments and vaccination studies in mice. This comprehensive approach provides a valuable application for identifying and selecting potential mucosal adjuvants.</p></sec><sec id="sec2-vetsci-12-00181"><title>2. Materials and Methods</title><sec id="sec2dot1-vetsci-12-00181"><title>2.1. Cells and Viruses</title><p>Porcine kidney cells (PK-15, BCRC #60057) and African green monkey kidney cells (Vero cells, BCRC #60013) were obtained from the Bioresource Collection and Research Center (BCRC), Taiwan. Both cell lines were cultured in Minimum Essential Medium Alpha Medium (&#x003b1;MEM, Gibco, New York, NY, USA), supplemented with 5% heat-inactivated fetal bovine serum (FBS, Gibco, USA), in a humidity-controlled incubator at 37 &#x000b0;C with 5% CO<sub>2</sub>. Cell lines were monitored for viability and sterility throughout the study period.</p><p>PED virus was isolated from infected pigs and propagated in Vero cells, as described previously [<xref rid="B17-vetsci-12-00181" ref-type="bibr">17</xref>]. Briefly, cells were inoculated with PEDV in the infected media &#x003b1;MEM supplemented with 5 &#x000b5;g/mL of Trypsin-TPCK (Sigma, Carlsbad, CA, USA) and 1% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic> Penicillin-Streptomycin (Gibco, USA) in a humidity-controlled incubator at 37 &#x000b0;C with 5% CO<sub>2</sub>. The cytopathic effects (CPE) were monitored daily to record clear signs of cell rounding, fusion, and detachment. After 72 h after infection, infected cells were lysed using the freeze&#x02013;thaw method and centrifuged at 2000&#x000d7; <italic toggle="yes">g</italic> for 10 min. Virus titer in the supernatant was determined using a 50% tissue culture infectious dose (TCID<sub>50</sub>) assay [<xref rid="B18-vetsci-12-00181" ref-type="bibr">18</xref>]. The viral suspension was adjusted to a final concentration of 10<sup>7</sup> TCID<sub>50</sub>/mL and heat-inactivated at 56 &#x000b0;C for 30 min. The inactivated virus was aliquoted and stored at &#x02212;80 &#x000b0;C until use.</p></sec><sec id="sec2dot2-vetsci-12-00181"><title>2.2. Establishment of Reporter Cell Line</title><p>To monitor NF-&#x003ba;B activation, a porcine kidney epithelial cell line (PK-15) expressing an NF-&#x003ba;B reporter gene was generated as follows: PK-15 cells were transduced with a lentiviral vector encoding the NF-&#x003ba;B consensus binding sequence, luciferase, and enhanced green fluorescent protein (eGFP). The lentivirus plasmid, pHAGE NFkB-TA-LUC-UBC-GFP-W, was a gift from Darrell Kotton (Addgene plasmid # 49343; <uri xlink:href="http://n2t.net/addgene:49343">http://n2t.net/addgene:49343</uri>; RRID: Addgene_49343, accessed on 12 February 2013). This dual reporter system enables independent tracking of successfully transduced cells via eGFP fluorescence and allows for real-time assessment of NF-&#x003ba;B activation through luciferase expression (<xref rid="vetsci-12-00181-f001" ref-type="fig">Figure 1</xref>A).</p><p>PK-15 cells were incubated overnight with lentivirus-containing supernatant in the presence of 5 &#x000b5;g/mL polybrene (Merck, Darmstadt, Germany) to enhance transduction efficiency. Subsequently, cells were harvested and analyzed for eGFP expression using flow cytometry (BD FACScan, BD Biosciences, Palo Alto, CA, USA) with data processed in FlowJo software version 10.8.1 (BD Biosciences, Palo Alto, CA, USA). Single eGFP-positive cells were sorted into individual tubes. The successfully transduced cell line, referred to as PK15-KBR, was selected and passaged for further studies.</p></sec><sec id="sec2dot3-vetsci-12-00181"><title>2.3. Flow Cytometry</title><p>Flow cytometry was utilized to assess the transduction efficiency of PK15-KBR cells, specifically measuring the percentage of GFP-positive cells. Briefly, 5 &#x000b5;L of 7-Amino-Actinomycin D (7-AAD) (BD Biosciences, Palo Alto, CA, USA) was added to get rid of dead cells. Flow cytometry was conducted using a BD FACScan instrument (BD Biosciences, USA), while cell sorting experiments were performed on a BD FACSMelody&#x02122; 4-Way Cell Sorter (BD Biosciences, Palo Alto, CA, USA). The data analysis was completed using FlowJo software version 10.8.1 (BD Biosciences, Palo Alto, CA, USA) to quantify transduction efficiency and evaluate cell population.</p></sec><sec id="sec2dot4-vetsci-12-00181"><title>2.4. Preparation of Plant Extracts (PEs)</title><p>A total of 224 crude extracts (PEs) were obtained from TFDA food ingredients reference plant extract library (TFDA-RD, Natural Product Libraries and High-throughput Screening Score, Kaohsiung Medical University). Whole plant sources from Taiwan were processed into extracts following standard protocols. Dried plant materials were soaked in cold methanol at room temperature for three days, with the process repeated three times to maximize extraction efficiency. The resulting aqueous extracts were weighed and dissolved in culture-grade dimethyl sulfoxide (DMSO, Merck, Darmstadt, Germany) to achieve a final concentration of 100 mg/mL for subsequent use.</p></sec><sec id="sec2dot5-vetsci-12-00181"><title>2.5. Quantification of NF-&#x01d0b;B Activation via TNF-&#x003b1; Stimulation</title><p>NF-&#x01d0b;B activation was quantified by measuring luciferase activity in TNF-&#x003b1; stimulated PK15-KBR cells using the Luciferase Assay System (Promega Corporation, Madison, WI, USA). Briefly, cells were seeded overnight on 96-well plates at 37 &#x000b0;C with 5% CO<sub>2</sub> to allow monolayer formation. Reporter cells were then incubated with tumor necrosis factor-alpha (TNF-&#x003b1;) at a concentration ranging from 0.625 to 10 ng/mL alongside DMSO controls at concentrations of 0 to 1% (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>). Cells were incubated at 37 &#x000b0;C with 5% CO<sub>2</sub> for 16 h. After incubation, the medium was removed, and cells were lysed with 50 &#x003bc;L of 1 &#x000d7; passive lysis buffer for 15 min at room temperature. Finally, 20 &#x003bc;L of the lysate was mixed with 50 &#x003bc;L of Luciferase Buffer for luciferase activity measurement, while another 20 &#x003bc;L of lysate was mixed with 50 &#x003bc;L of Alamar Blue for cell viability assessment. Both luciferase activity and cell viability were measured using the GloMax-Multi+ Detection System (Promega Corporation, Madison, WI, USA).</p></sec><sec id="sec2dot6-vetsci-12-00181"><title>2.6. High-Throughput Screening Assays</title><p>High-throughput screening was performed to evaluate NF-&#x003ba;B signaling in PK15-KBR cells in response to plant extracts (PEs). A monolayer of 10,000 cells per well was treated with PEs at a final concentration of 10 &#x000b5;g/mL. TNF-&#x003b1; was used as the positive control at 10 ng/mL, and DMSO served as the solvent control at 0.1% (<italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>). Cells were inoculated at 37 &#x000b0;C with 5% CO<sub>2</sub> for 16 h. After incubation, the medium was removed, the cells were lysed with 50 &#x003bc;L of 1 &#x000d7; passive lysis buffer for 15 min at room temperature. Finally, 20 &#x003bc;L of the lysate was mixed with 50 &#x003bc;L of Luciferase Buffer for luciferase activity measurement, and another 20 &#x003bc;L of lysate was mixed with 50 &#x003bc;L of Alamar Blue to assess cell viability. Both luciferase activity and cell viability were measured using GloMax-Multi+ Detection System (Promega Corporation, Madison, WI, USA).</p></sec><sec id="sec2dot7-vetsci-12-00181"><title>2.7. CCK-8 Assays</title><p>Cytotoxicity was evaluated using the colorimetric Cell Counting Kit-8 (CCK-8, Abcam, Taipei, Taiwan), a sensitive assay for quantifying cell viability. A monolayer of 5000 PK-15 cells was pre-incubated in a 96-well plate overnight in a humidified incubator at 37 &#x000b0;C with 5% CO<sub>2</sub>. The following day, 10 &#x003bc;L of PEs at different concentrations (1&#x02014;1000 &#x000b5;g/mL) was added to wells. DMSO at 0.01% <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic> served as the control group, while &#x003b1;MEM medium was used as a background. The cells were incubated at 37 &#x000b0;C for 24 h. Finally, 10 &#x003bc;L of CCK-8 solution was added to each well and incubated at 37 &#x000b0;C for 3 h. Absorbance values at 450 nm were measured using a microplate reader. Cytotoxicity was calculated using the following formula:<disp-formula id="FD1-vetsci-12-00181"><mml:math id="mm1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>C</mml:mi><mml:mi>y</mml:mi><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>x</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mo>%</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfenced separators="|"><mml:mrow><mml:mtext>&#x000a0;</mml:mtext><mml:mstyle scriptlevel="0" displaystyle="true"><mml:mfrac><mml:mrow><mml:mi>A</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mi>s</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>A</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>n</mml:mi><mml:mi>t</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mi>l</mml:mi><mml:mi>l</mml:mi><mml:mi>s</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>A</mml:mi><mml:mi>b</mml:mi><mml:mi>s</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mtext>&#x000a0;</mml:mtext><mml:mi>b</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>k</mml:mi><mml:mi>g</mml:mi><mml:mi>r</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>n</mml:mi><mml:mi>d</mml:mi></mml:mrow></mml:mfrac></mml:mstyle><mml:mtext>&#x000a0;</mml:mtext></mml:mrow></mml:mfenced><mml:mtext>&#x000a0;</mml:mtext><mml:mo>&#x000d7;</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:mrow></mml:math></disp-formula></p></sec><sec id="sec2dot8-vetsci-12-00181"><title>2.8. Toxicity Assessment in Mice Study</title><p>The toxic effects of intramuscular injections of PEs were evaluated using a modified methodology in a study involving 25 seven-week-old ICR mice. The mice were randomly divided into five groups (<italic toggle="yes">n</italic> = 5) as follows: (1) 25 mg/kg body weight (bw) of chamomile extract (Chamomile_Low), (2) 50 mg/kg bw of chamomile extract (Chamomile_High), (3) 25 mg/kg bw of mulberry extract (Mulberry_Low), (4) 50 mg/kg bw of mulberry extract (Mulberry_High), and (5) phosphate-buffered saline (PBS) as the control group (<xref rid="vetsci-12-00181-t001" ref-type="table">Table 1</xref>) [<xref rid="B19-vetsci-12-00181" ref-type="bibr">19</xref>]. Each mouse received 100 &#x000b5;L of the assigned treatment via intramuscular injection. The concentration of DMSO was maintained below the maximum permissible concentration of 10% in all control and treatment group samples. Signs of toxicity, including adverse symptoms and mortality, were closely monitored and recorded during the first 24 h post-injection.</p></sec><sec id="sec2dot9-vetsci-12-00181"><title>2.9. Experimental Design and Sample Collection</title><p>For intramuscular injection, seven-week-old female ICR mice were obtained from BioLASCO Taiwan Co., Ltd. (Taipei, Taiwan) and randomly assigned to four groups (<italic toggle="yes">n</italic> = 5) as follows: (1) in-house inactivated PEDV (IM), (2) in-house inactivated PEDV with 6 mg/kg bw of chamomile extract (IM 120), (3) in-house inactivated PEDV with 24 mg/kg bw of chamomile extract (IM 480), and (4) PBS as the control (<xref rid="vetsci-12-00181-t002" ref-type="table">Table 2</xref>). Each vaccine was formulated with the water-in-oil adjuvant MONTANIDE&#x02122; ISA 206 VG (Seppic, Castres, France) in a 1:1 ratio. Each mouse received intramuscular injections of 100 &#x000b5;L on days 0 and 14, following the protocol established in our previous study [<xref rid="B20-vetsci-12-00181" ref-type="bibr">20</xref>].</p><p>For oral administration, seven-week-old female ICR mice were obtained from BioLASCO Taiwan Co., Ltd. and divided into four groups (<italic toggle="yes">n</italic> = 5) as follows: (1) in-house inactivated PEDV (OR), (2) in-house inactivated PEDV with 6 mg/kg bw of chamomile extract (OR 120), (3) in-house inactivated PEDV with 24 mg/kg bw of chamomile extract (OR 480), and (4) PBS as the control (<xref rid="vetsci-12-00181-t002" ref-type="table">Table 2</xref>). Vaccines for oral administration were formulated with the water-in-oil adjuvant MONTANIDE&#x02122; GR01 (Seppic, France) in a 7:3 ratio. Mice were administered 100 &#x000b5;L doses orally once per week for four consecutive weeks [<xref rid="B21-vetsci-12-00181" ref-type="bibr">21</xref>].</p><p>Serum samples were collected weekly, while the intestinal fluid samples were obtained on day 28 for subsequent immune evaluation.</p></sec><sec id="sec2dot10-vetsci-12-00181"><title>2.10. Indirect Enzyme-Linked Immunosorbent Assay (ELISA)</title><p>ELISA were conducted to qualify total IgG antibodies specific to PEDV in mouse sera. Briefly, the sera were separated from whole blood by centrifugation at 800&#x000d7; <italic toggle="yes">g</italic> for 5 min and stored at &#x02212;20 &#x000b0;C until use. In-house inactivated PEDV was coated onto 96-well plates at a concentration of 100 TCID<sub>50</sub> per well and incubated at 4 &#x000b0;C overnight. The following day, plates were blocked with 3% BSA at 37 &#x000b0;C in one hour. After washing with PBST, four-fold diluted sera were added into the wells and incubated at 37 &#x000b0;C for 1.5 h as a primary antibody. Subsequently, plates were incubated with anti-mouse IgG or IgA antibody-peroxidase conjugate (Sigma, Carlsbad, CA, USA) diluted to 1:10,000 as a secondary antibody at 37 &#x000b0;C for one hour. After the final wash with PBST, TMB substrate solution was added for color development. Finally, TMB Stop Solution was applied to stop the reaction. The color intensity was quantified at a wavelength of 450 nm using a microplate reader, reflecting the relative antibody levels.</p></sec><sec id="sec2dot11-vetsci-12-00181"><title>2.11. Statistical Methods</title><p>NF-&#x003ba;B determination and cytotoxicity tests were repeated independently at least three times to ensure data reproducibility. Statistical analyses and graphical presentations were performed using JASP version 0.19.3.0 JASP software (NIEUW-VENNEP, Netherlands) and GraphPad Prism version 10 (GraphPad Software, San Diego, CA, USA). Non-parametric Kruskal&#x02013;Wallis tests were conducted for cytotoxicity assays, NF-&#x003ba;B quantification, and determination of IgA antibody titers. An independent sample <italic toggle="yes">t</italic>-test was used to determine the difference between two samples in this group. Two-way ANOVA with Dunnett&#x02019;s post hoc test was applied to evaluate IgG antibody titers, followed by GLMMs for each of the models. Data are presented as the mean of the triplicate of antibody titer per subject with &#x000b1; SEM. Statistical significance was denoted as follows: <italic toggle="yes">p</italic> &#x02264; 0.05 (*), <italic toggle="yes">p</italic> &#x02264; 0.01(**), <italic toggle="yes">p</italic> &#x02264; 0.001 (***), and <italic toggle="yes">p</italic> &#x02264; 0.0001 (****).</p></sec></sec><sec sec-type="results" id="sec3-vetsci-12-00181"><title>3. Results</title><sec id="sec3dot1-vetsci-12-00181"><title>3.1. Establishment of PK15-KBR Cells</title><p>To facilitate real-time tracking of NF-&#x003ba;B activation, we developed a reporter cell platform, PK15-KBR cells, incorporating the lenti-NF-&#x003ba;B-luc-GFP plasmid. Transduction efficiency was evaluated by measuring the mean fluorescence intensity of GFP-positive cells through flow cytometry. Initial analysis revealed that approximately 4% of the infected PK-15 cells expressed green fluorescence, with a dramatic increase to over 95% after cell sorting. This high level of transduction efficiency was maintained stable for up to ten passages. However, a marked reduction in transduction proficiency was observed after freeze&#x02013;thaw cycles, suggesting the necessity of repeated cell sorting to maintain a sufficient population of transduced cells for downstream applications. These observations are summarized in <xref rid="vetsci-12-00181-f002" ref-type="fig">Figure 2</xref>.</p></sec><sec id="sec3dot2-vetsci-12-00181"><title>3.2. NF-&#x003ba;B Activation by TNF-&#x003b1; Stimulation in a Dose-Dependent Manner</title><p>To validate the functionality of the lenti-NF-&#x003ba; B-luc-GFP construct in PK15-KBR cells, we conducted preliminary testing using TNF-&#x003b1;, a well-known activator of NF-&#x003ba;B signaling (<xref rid="vetsci-12-00181-f003" ref-type="fig">Figure 3</xref>A). PK15-KBR cells were exposed to TNF-&#x003b1; at concentrations ranging from 0.625 to 10 ng/mL. Luciferase activity in PK15-KBR cells showed a significant dose-dependent increase compared to the untreated control group. Luciferase activity was three-fold higher than the control at the lowest concentration (0.625 ng/mL), after which it experienced a rise to seven-fold at highest concentration (<italic toggle="yes">p</italic> &#x0003c; 0.001) (a detailed analysis is provided in <xref rid="app1-vetsci-12-00181" ref-type="app">Supplementary File S1</xref>). These results demonstrate that TNF-&#x003b1; effectively induces NF-&#x003ba;B-driven luciferase activities in PK15-KBR cells in a dose-dependent manner.</p><p>Further analysis revealed that the addition of 1% DMSO impacted luciferase responses under TNF-&#x003b1; stimulation (<xref rid="vetsci-12-00181-f003" ref-type="fig">Figure 3</xref>C). A consistent increase in luciferase activity was observed across all TNF-&#x003b1; concentrations (0.625 to 10 ng/mL), regardless of DMSO presence (<xref rid="vetsci-12-00181-f003" ref-type="fig">Figure 3</xref>, panel A and B). However, cells treated with 1% DMSO exhibited a notable reduction in overall luciferase activity compared to the cells stimulated without DMSO. At lower TNF-&#x003b1; concentrations (0.625 to 1.25 ng/mL), NF-&#x003ba;B-driven luminescence increased less than two-fold, whereas at higher concentrations, the increase was approximately three-fold with statistical significance (a detailed analysis is provided in <xref rid="app1-vetsci-12-00181" ref-type="app">Supplementary File S1</xref>).</p><p>In the final trial, luminescence responses were systematically evaluated under different experimental conditions, including cell numbers, drug action time, and solvent concentrations. TNF-&#x003b1; at 10 ng/mL was defined as the positive control, and DMSO served as the solvent control (<xref rid="vetsci-12-00181-f003" ref-type="fig">Figure 3</xref>C). Stimulation with TNF-&#x003b1; resulted in a significant increase in luminescence compared to the solvent control group (<italic toggle="yes">p</italic> &#x0003c; 0.001) (a detailed analysis is provided in <xref rid="app1-vetsci-12-00181" ref-type="app">Supplementary File S1</xref>). To assess the robustness of the assay for high-throughput screening, the Z&#x02019; factor was calculated from luminescence values of positive and negative controls. The Z&#x02019; value of 0.68 confirmed the suitability of the assay for high-throughput applications.</p><p>Collectively, these findings confirm that TNF-&#x003b1; induces NF-&#x003ba; B-driven luciferase activity in PK15-KBR cells in a dose-dependent manner, with or without the presence of DMSO, although DMSO may suppress the magnitude of the luminescence response.</p></sec><sec id="sec3dot3-vetsci-12-00181"><title>3.3. NF-&#x003ba;B Activation by Chamomile Extract in a Dose-Dependent Manner</title><p>A total of 224 crude plant extracts from the TFDA-RD library were screened for their ability to activate NF-&#x003ba;B signaling. Among the tested extracts, chamomile, <italic toggle="yes">Boerhaavia diffusa</italic> and mulberry demonstrated NF-&#x003ba;B activation, while the remaining extracts produced background luminescence levels comparable to the solvent control group.</p><p>Subsequent experiments confirmed the NF-&#x003ba;B activation potential of these three extracts across five different concentrations. Chamomile exhibited clear dose-dependent activation of NF-&#x003ba;B, while <italic toggle="yes">Boerhaavia diffusa</italic> and mulberry showed partial dose dependence compared to the control group (<xref rid="vetsci-12-00181-f004" ref-type="fig">Figure 4</xref>). These results highlight chamomile extract as the most promising candidate among the screened PEs, with its ability to induce NF-&#x003ba;B activation potentially supporting its role in eliciting an effective immune response.</p></sec><sec id="sec3dot4-vetsci-12-00181"><title>3.4. Toxicity Assessment of PEs In Vitro and In Vivo</title><p>In vitro cytotoxicity is a useful method for evaluating biological materials due to its simplicity, speed, and high sensitivity [<xref rid="B22-vetsci-12-00181" ref-type="bibr">22</xref>]. Overall, there was no statistical difference between the treatment groups, but there was a clear difference in different concentrations. Of the three screened PEs, mulberry and boerhavia diffusa exhibited mild cytotoxicity at 1000 &#x000b5;g/mL (<italic toggle="yes">p</italic> &#x0003c; 0.5) (a detailed analysis is provided in <xref rid="app1-vetsci-12-00181" ref-type="app">Supplementary File S2</xref>). Most results were well below the 30% cytotoxicity threshold, meeting the standard outlined in ISO 10993-5 [<xref rid="B23-vetsci-12-00181" ref-type="bibr">23</xref>]. At tested concentrations of 10, 100, and 1000 &#x000b5;g/mL, all three extracts showed no significant cytotoxic effects compared to control groups (<xref rid="vetsci-12-00181-f005" ref-type="fig">Figure 5</xref>).</p><p>The potential in vivo toxicity of chamomile and mulberry was further evaluated in a mouse model (<xref rid="vetsci-12-00181-f006" ref-type="fig">Figure 6</xref>). Mice treated with these extracts displayed no abnormal behaviors or adverse clinical signs across all experimental groups during the observation period. These findings confirmed that both chamomile and mulberry were safe for further experimentation.</p></sec><sec id="sec3dot5-vetsci-12-00181"><title>3.5. PEDV-Specific Antibody Titers Increased by Chamomile-Adjuvanted and In-House Inactivated PED Vaccines</title><p>To assess the impact of PEs on immunogenicity and to bridge the in vitro NF-&#x003ba;B activation with in vivo immune responses, chamomile was selected for further evaluation due to its distinct in vitro effects. Serum IgG antibody responses were measured in vaccinated mice using an indirect ELISA with in-house inactivated PEDV as the coating antigen (<xref rid="vetsci-12-00181-f007" ref-type="fig">Figure 7</xref>).</p><p>Mice administered via injection demonstrated markedly higher serum antibody titers at all time intervals in comparison to those receiving the oral vaccination. In both vaccination methods, antibody responses increased in a time-dependent manner, with the lowest titers recorded on day 7 and the highest on day 28, indicating the immune system&#x02019;s response to the vaccine matures over time. Significant differences were seen among the oral vaccine groups on day 14. Mice administered the chamomile-adjuvanted PEDV vaccination exhibited substantially higher IgG antibody levels compared to those in the inactivated (OR) group (OR 120, <italic toggle="yes">p</italic> &#x0003c; 0.01; OR 480, <italic toggle="yes">p</italic> &#x0003c; 0.05). In contrast, the intramuscular (I.M.) vaccinations did not show any significant effect from the presence of chamomile on IgG antibody titers (detailed analysis is provided in <xref rid="app1-vetsci-12-00181" ref-type="app">Supplementary File S3</xref>). This indicates that while chamomile may enhance oral vaccine formulations, its impact is not observed in injectable forms. A key finding from this study was that the addition of chamomile to the vaccine formulation enhanced IgG antibody responses in serum, starting from day 14 post-vaccination in the oral vaccination groups. This finding underscores the potential of natural adjuvants in vaccine development and emphasizes the need for tailored approaches based on vaccination routes to optimize immune responses.</p></sec><sec id="sec3dot6-vetsci-12-00181"><title>3.6. IgA Antibody Enhancement in Mice Vaccinated with Chamomile as an Adjuvant</title><p>IgA antibody responses were evaluated in intestinal fluid samples collected on day 28 following the first vaccination, using indirect ELISA with in-house inactivated PEDV as the coated antigen (<xref rid="vetsci-12-00181-f008" ref-type="fig">Figure 8</xref>). The OR 480 group of mice exhibited the highest IgA antibody titers compared to the control group, although this difference was not statistically significant. Similarly, no significant effect from the addition of chamomile on IgA titers was observed across the injection groups (a detailed analysis is provided in <xref rid="app1-vetsci-12-00181" ref-type="app">Supplementary File S4</xref>). These findings suggest a potential trend indicating that chamomile may enhance IgA production in mice and underscore the need for further investigation into its mechanisms of action and implications for vaccine development.</p></sec></sec><sec sec-type="discussion" id="sec4-vetsci-12-00181"><title>4. Discussion</title><p>Vaccines delivered through the mucosa can efficiently boost both innate and acquired immune responses [<xref rid="B3-vetsci-12-00181" ref-type="bibr">3</xref>,<xref rid="B24-vetsci-12-00181" ref-type="bibr">24</xref>]. Traditional animal-based studies can be reliable but time-consuming and costly. To address these limitations, high-throughput assays have emerged as efficient alternatives for predicting the potential of novel materials. Combining in vitro assays with animal models allows for a more comprehensive and accurate assessment of novel adjuvanticity by leveraging the strengths of both methods [<xref rid="B25-vetsci-12-00181" ref-type="bibr">25</xref>]. An ideal predictive method should be highly accurate, fast, reliable, cost-effective, and require minimal sample quantities. Our study incorporates these principles to refine the process of adjuvant selection.</p><p>The activation of NF-&#x003ba;B signaling in PK15-KBR cells served as a robust platform for cellular screening in this study. Among the three screened plant extracts, chamomile upregulated significant NF-&#x003ba;B activity in vitro and enhanced humoral immune responses in vivo. Previous studies have highlighted the predictive value of in vitro NF-&#x003ba;B activation in correlating with in vivo immune responses, establishing its reliability as a model system. For instance, TLR reporter cell lines, such as those from Invitrogen, have been widely used to assess TLR activation and its downstream signaling, including NF-&#x003ba;B activity, which strongly correlates with immune activation in vivo [<xref rid="B26-vetsci-12-00181" ref-type="bibr">26</xref>]. Consistent with these findings, our study showed a dose-dependent activation of NF-&#x003ba;B in PK15-KBR cells following chamomile treatment, which corresponded with a dose-dependent increase in IgA antibody titers when used as an oral adjuvant with an inactivated PEDV vaccine. These results highlight the predictive link between in vitro NF-&#x003ba;B activation and in vivo immune responses, emphasizing chamomile&#x02019;s potential as an immunomodulator in vaccine formulations.</p><p>In vitro studies commonly use mucosa-associated cell lines to explore activities related to adjuvanticity. Immortalized cell lines, such as the epithelial cells TC-1, dendritic cells Jaws II, and macrophage Raw 264.7, have been widely used due to their reliability and practicality [<xref rid="B25-vetsci-12-00181" ref-type="bibr">25</xref>]. Among these, epithelial cells are particularly advantageous for the high-throughput screening of materials that impact mucosa function [<xref rid="B27-vetsci-12-00181" ref-type="bibr">27</xref>]. While primary intestine cell-derived models may offer greater physiological relevance for evaluating mucosal adjuvants for PEDV vaccinations, their cultivation complexity limits broader applicability [<xref rid="B9-vetsci-12-00181" ref-type="bibr">9</xref>]. The PK-15 porcine epithelial cell line provides a suitable alternative due to its broad expression of immunological receptors, making it relevant in various bioactivity assays [<xref rid="B28-vetsci-12-00181" ref-type="bibr">28</xref>]. The dual reporter system in PK15-KBR cells offers distinct advantages: GFP intracellular expression facilitates the sorting of positively transduced cells using flow cytometry, while luciferase secretion enables quick and efficient readouts. Moreover, NF-&#x01d0b;B-based reporter cell lines, such as PK15-KBR, have been instrumental in identifying new immunomodulatory compounds and revealing cytokine expression mechanisms [<xref rid="B13-vetsci-12-00181" ref-type="bibr">13</xref>]. This aligns with the critical role of NF-&#x01d0b;B signaling in epithelial cells for immune regulation [<xref rid="B4-vetsci-12-00181" ref-type="bibr">4</xref>].</p><p>Recent research underscores the immunomodulatory potential of natural products, including plant-derived compounds, in the development of novel mucosal adjuvants [<xref rid="B29-vetsci-12-00181" ref-type="bibr">29</xref>]. Our study reveals a novel role of chamomile as an immunomodulator, enhancing NF-&#x003ba;B activation and antibody responses when used as a supplement with an orally inactivated PEDV vaccine. Unlike earlier studies that emphasized chamomile&#x02019;s ability to suppress NF-&#x003ba;B activity via I&#x003ba;B kinase inhibition and reduced RelA/p65 nuclear translocation in murine macrophages [<xref rid="B30-vetsci-12-00181" ref-type="bibr">30</xref>], our findings demonstrate a dose-dependent activation of NF-&#x003ba;B in PK15-KBR cells. This outcome underscores the complexity of chamomile&#x02019;s immune interactions, which may vary depending on dose, formulation, or cellular context. Moreover, the oral administration of chamomile may enhance IgA production in certain treatments or conditions, in contrast to intramuscular administration, which showed no notable improvement in immune response. This observation suggests that chamomile&#x02019;s immunostimulatory effects are enhanced by interaction with gut-associated lymphoid tissues (GALT), highlighting its potential as a strategic oral adjuvant.</p><p>Despite its promising findings, this study has limitations and warrants further research to refine the PK15-KBR reporter cell system and explore the mechanisms underlying chamomile&#x02019;s immunomodulatory effects. The precise immune activation pathways remain unclear. Previous studies have focused on chamomile&#x02019;s anti-inflammatory and antioxidant properties, attributed to bioactive constituents such as apigenin, bisabolol, and polysaccharides [<xref rid="B30-vetsci-12-00181" ref-type="bibr">30</xref>,<xref rid="B31-vetsci-12-00181" ref-type="bibr">31</xref>]. Future studies should isolate and evaluate the contributions of these compounds to NF-&#x003ba;B activation in PK-15 cells and elucidate the mechanisms underlying this activity. NF-&#x003ba;B activation involves two major signaling pathways: the canonical pathway, which responds to diverse stimuli, and the noncanonical pathway, which selectively reacts to specific ligands from the TNFR superfamily [<xref rid="B4-vetsci-12-00181" ref-type="bibr">4</xref>]. Further research is essential to understand how these pathways interact and regulate immune responses, tissue integrity, and inflammation in the context of chamomile-based immunomodulation. In addition, while the OR 480 group&#x02019;s higher IgA levels are notable, further studies in larger animals are necessary to clarify aspects of the immune response beyond IgA production, such as T cell activation and cytokine profiles. This could provide a more comprehensive understanding of its role in mucosal immunity.</p></sec><sec sec-type="conclusions" id="sec5-vetsci-12-00181"><title>5. Conclusions</title><p>This study highlights the potential of the PK15-KBR reporter cell line as a robust, high-throughput platform for screening novel epithelial cell-targeted adjuvants. Among the tested extracts, three effectively induced NF-&#x003ba;B activation, with the chamomile extract demonstrating concentration-dependent activation in vitro and enhanced immune responses in mice. These findings establish PK15-KBR as a promising tool for identifying mucosal adjuvants, paving the way for future advancements in mucosal vaccine development.</p></sec></body><back><ack><title>Acknowledgments</title><p>Thanks to the members of the Laboratory of Natural Product Libraries and High-throughput Screening Core, College of Pharmacy, Kaohsiung Medical University, and the members of the Laboratory of Vaccines and Adjuvants, College of Veterinary Medicine, and National Pingtung University of Science and Technology for their excellent technical support.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-vetsci-12-00181"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xlink:href="https://www.mdpi.com/article/10.3390/vetsci12020181/s1">https://www.mdpi.com/article/10.3390/vetsci12020181/s1</uri>.</p><supplementary-material id="vetsci-12-00181-s001" position="float" content-type="local-data"><media xlink:href="vetsci-12-00181-s001.zip"/></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Conceptualization: Y.-C.C. and C.-H.Y., data curation: N.-T.H., formal analysis: N.-T.H. and T.-D.D., investigation: Y.-C.C. and C.-H.Y., methodology: T.-D.D., resources: Y.-C.C. and C.-H.Y., supervision: Y.-C.C. and C.-H.Y., validation: N.-T.H. and A.M., visualization: N.-T.H. and H.A., writing&#x02014;original draft: N.-T.H., writing&#x02014;review and editing: A.M. and H.A. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>The animal study followed NIH guidelines for laboratory animals. No animals were harmed during the collection of blood and fecal samples. Ethical approval for this study was granted by IACUC, NPUST-110-140, date: 1 January 2023.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>The original contributions presented in the study are included in the article/<xref rid="app1-vetsci-12-00181" ref-type="app">Supplementary Materials</xref>; further inquiries can be directed to the corresponding author.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>No potential conflict of interest was reported by the author(s).</p></notes><ref-list><title>References</title><ref id="B1-vetsci-12-00181"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wullaert</surname><given-names>A.</given-names></name>
<name><surname>Bonnet</surname><given-names>M.C.</given-names></name>
<name><surname>Pasparakis</surname><given-names>M.</given-names></name>
</person-group><article-title>NF-kappaB in the regulation of epithelial homeostasis and inflammation</article-title><source>Cell Res.</source><year>2011</year><volume>21</volume><fpage>146</fpage><lpage>158</lpage><pub-id pub-id-type="doi">10.1038/cr.2010.175</pub-id><pub-id pub-id-type="pmid">21151201</pub-id>
</element-citation></ref><ref id="B2-vetsci-12-00181"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tian</surname><given-names>k.</given-names></name>
<name><surname>Lv</surname><given-names>C.</given-names></name>
<name><surname>Xiao</surname><given-names>Y.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
</person-group><article-title>Porcine epidemic diarrhea virus: Current insights</article-title><source>Virus Adapt. Treat.</source><year>2016</year><volume>8</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.2147/VAAT.S107275</pub-id></element-citation></ref><ref id="B3-vetsci-12-00181"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hackett</surname><given-names>C.J.</given-names></name>
</person-group><article-title>Innate immune activation as a broad-spectrum biodefense strategy: Prospects and research challenges</article-title><source>J. Allergy Clin. Immunol.</source><year>2003</year><volume>112</volume><fpage>686</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1016/S0091-6749(03)02025-6</pub-id><pub-id pub-id-type="pmid">14564345</pub-id>
</element-citation></ref><ref id="B4-vetsci-12-00181"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pasparakis</surname><given-names>M.</given-names></name>
</person-group><article-title>Role of NF-kappaB in epithelial biology</article-title><source>Immunol. Rev.</source><year>2012</year><volume>246</volume><fpage>346</fpage><lpage>358</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2012.01109.x</pub-id><pub-id pub-id-type="pmid">22435565</pub-id>
</element-citation></ref><ref id="B5-vetsci-12-00181"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Lin</surname><given-names>L.</given-names></name>
<name><surname>Pan</surname><given-names>G.</given-names></name>
<name><surname>Zhang</surname><given-names>S.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Zhang</surname><given-names>M.</given-names></name>
<name><surname>Xuan</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>You</surname><given-names>Z.</given-names></name>
</person-group><article-title>Quzhou Fructus Aurantii Extract suppresses inflammation via regulation of MAPK, NF-kappaB, and AMPK signaling pathway</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>1593</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-58566-7</pub-id><pub-id pub-id-type="pmid">32005962</pub-id>
</element-citation></ref><ref id="B6-vetsci-12-00181"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Adesso</surname><given-names>S.</given-names></name>
<name><surname>Russo</surname><given-names>R.</given-names></name>
<name><surname>Quaroni</surname><given-names>A.</given-names></name>
<name><surname>Autore</surname><given-names>G.</given-names></name>
<name><surname>Marzocco</surname><given-names>S.</given-names></name>
</person-group><article-title>Astragalus membranaceus Extract Attenuates Inflammation and Oxidative Stress in Intestinal Epithelial Cells via NF-kappaB Activation and Nrf2 Response</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>800</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19030800</pub-id><pub-id pub-id-type="pmid">29534459</pub-id>
</element-citation></ref><ref id="B7-vetsci-12-00181"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kumar</surname><given-names>A.</given-names></name>
<name><surname>Sharma</surname><given-names>A.</given-names></name>
<name><surname>Tirpude</surname><given-names>N.V.</given-names></name>
<name><surname>Padwad</surname><given-names>Y.</given-names></name>
<name><surname>Hallan</surname><given-names>V.</given-names></name>
<name><surname>Kumar</surname><given-names>S.</given-names></name>
</person-group><article-title>Plant-derived immuno-adjuvants in vaccines formulation: A promising avenue for improving vaccines efficacy against SARS-CoV-2 virus</article-title><source>Pharmacol. Rep.</source><year>2022</year><volume>74</volume><fpage>1238</fpage><lpage>1254</lpage><pub-id pub-id-type="doi">10.1007/s43440-022-00418-4</pub-id><pub-id pub-id-type="pmid">36125739</pub-id>
</element-citation></ref><ref id="B8-vetsci-12-00181"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Shi</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Yao</surname><given-names>H.</given-names></name>
<name><surname>Kou</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>W.</given-names></name>
<name><surname>Chen</surname><given-names>B.</given-names></name>
<name><surname>Wu</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
<name><surname>Pei</surname><given-names>C.</given-names></name>
<name><surname>Huang</surname><given-names>D.</given-names></name>
<etal/>
</person-group><article-title>Oral Chinese Herbal Medicine on Immune Responses During Coronavirus Disease 2019: A Systematic Review and Meta-Analysis</article-title><source>Front Med</source><year>2021</year><volume>8</volume><fpage>685734</fpage><pub-id pub-id-type="doi">10.3389/fmed.2021.685734</pub-id></element-citation></ref><ref id="B9-vetsci-12-00181"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Buckner</surname><given-names>D.</given-names></name>
<name><surname>Wilson</surname><given-names>S.</given-names></name>
<name><surname>Kurk</surname><given-names>S.</given-names></name>
<name><surname>Hardy</surname><given-names>M.</given-names></name>
<name><surname>Miessner</surname><given-names>N.</given-names></name>
<name><surname>Jutila</surname><given-names>M.A.</given-names></name>
</person-group><article-title>Use of early passage fetal intestinal epithelial cells in semi-high-throughput screening assays: An approach to identify new innate immune system adjuvants</article-title><source>J. Biomol. Screen.</source><year>2006</year><volume>11</volume><fpage>664</fpage><lpage>671</lpage><pub-id pub-id-type="doi">10.1177/1087057106289876</pub-id><pub-id pub-id-type="pmid">16923848</pub-id>
</element-citation></ref><ref id="B10-vetsci-12-00181"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>El-Murr</surname><given-names>T.</given-names></name>
<name><surname>Patel</surname><given-names>A.</given-names></name>
<name><surname>Sedlak</surname><given-names>C.</given-names></name>
<name><surname>D&#x02019;Souza-Lobo</surname><given-names>B.</given-names></name>
</person-group><article-title>Evaluating dendritic cells as an in vitro screening tool for immunotherapeutic formulations</article-title><source>J. Immunol. Methods</source><year>2018</year><volume>459</volume><fpage>55</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2018.05.005</pub-id><pub-id pub-id-type="pmid">29800576</pub-id>
</element-citation></ref><ref id="B11-vetsci-12-00181"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vandebriel</surname><given-names>R.</given-names></name>
<name><surname>Hoefnagel</surname><given-names>M.M.</given-names></name>
</person-group><article-title>Dendritic cell-based in vitro assays for vaccine immunogenicity</article-title><source>Hum. Vaccin. Immunother.</source><year>2012</year><volume>8</volume><fpage>1323</fpage><lpage>1325</lpage><pub-id pub-id-type="doi">10.4161/hv.21350</pub-id><pub-id pub-id-type="pmid">22951585</pub-id>
</element-citation></ref><ref id="B12-vetsci-12-00181"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Radakovics</surname><given-names>K.</given-names></name>
<name><surname>Battin</surname><given-names>C.</given-names></name>
<name><surname>Leitner</surname><given-names>J.</given-names></name>
<name><surname>Geiselhart</surname><given-names>S.</given-names></name>
<name><surname>Paster</surname><given-names>W.</given-names></name>
<name><surname>Stockl</surname><given-names>J.</given-names></name>
<name><surname>Hoffmann-Sommergruber</surname><given-names>K.</given-names></name>
<name><surname>Steinberger</surname><given-names>P.</given-names></name>
</person-group><article-title>A Highly Sensitive Cell-Based TLR Reporter Platform for the Specific Detection of Bacterial TLR Ligands</article-title><source>Front. Immunol.</source><year>2021</year><volume>12</volume><elocation-id>817604</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2021.817604</pub-id><pub-id pub-id-type="pmid">35087538</pub-id>
</element-citation></ref><ref id="B13-vetsci-12-00181"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mock</surname><given-names>J.</given-names></name>
<name><surname>Pellegrino</surname><given-names>C.</given-names></name>
<name><surname>Neri</surname><given-names>D.</given-names></name>
</person-group><article-title>A universal reporter cell line for bioactivity evaluation of engineered cytokine products</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>3234</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-60182-4</pub-id><pub-id pub-id-type="pmid">32094407</pub-id>
</element-citation></ref><ref id="B14-vetsci-12-00181"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ortega</surname><given-names>R.A.</given-names></name>
<name><surname>Barham</surname><given-names>W.</given-names></name>
<name><surname>Sharman</surname><given-names>K.</given-names></name>
<name><surname>Tikhomirov</surname><given-names>O.</given-names></name>
<name><surname>Giorgio</surname><given-names>T.D.</given-names></name>
<name><surname>Yull</surname><given-names>F.E.</given-names></name>
</person-group><article-title>Manipulating the NF-kappaB pathway in macrophages using mannosylated, siRNA-delivering nanoparticles can induce immunostimulatory and tumor cytotoxic functions</article-title><source>Int. J. Nanomed.</source><year>2016</year><volume>11</volume><fpage>2163</fpage><lpage>2177</lpage><pub-id pub-id-type="doi">10.2147/IJN.S93483</pub-id><pub-id pub-id-type="pmid">27274241</pub-id>
</element-citation></ref><ref id="B15-vetsci-12-00181"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ding</surname><given-names>Z.</given-names></name>
<name><surname>An</surname><given-names>K.</given-names></name>
<name><surname>Xie</surname><given-names>L.</given-names></name>
<name><surname>Wu</surname><given-names>W.</given-names></name>
<name><surname>Zhang</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>D.</given-names></name>
<name><surname>Fang</surname><given-names>Y.</given-names></name>
<name><surname>Chen</surname><given-names>H.</given-names></name>
<name><surname>Xiao</surname><given-names>S.</given-names></name>
<name><surname>Fang</surname><given-names>L.</given-names></name>
</person-group><article-title>Transmissible gastroenteritis virus infection induces NF-kappaB activation through RLR-mediated signaling</article-title><source>Virology</source><year>2017</year><volume>507</volume><fpage>170</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2017.04.024</pub-id><pub-id pub-id-type="pmid">28448848</pub-id>
</element-citation></ref><ref id="B16-vetsci-12-00181"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>C.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<name><surname>Cheng</surname><given-names>S.</given-names></name>
<name><surname>Charreyre</surname><given-names>C.</given-names></name>
<name><surname>Audonnet</surname><given-names>J.C.</given-names></name>
<name><surname>Chen</surname><given-names>P.</given-names></name>
<name><surname>He</surname><given-names>Q.</given-names></name>
</person-group><article-title>Porcine coronin 1A contributes to nuclear factor-kappa B (NF-kappaB) inactivation during Haemophilus parasuis infection</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e103904</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0103904</pub-id><pub-id pub-id-type="pmid">25093672</pub-id>
</element-citation></ref><ref id="B17-vetsci-12-00181"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murtaza</surname><given-names>A.</given-names></name>
<name><surname>Hoa</surname><given-names>N.T.</given-names></name>
<name><surname>Dieu-Huong</surname><given-names>D.</given-names></name>
<name><surname>Afzal</surname><given-names>H.</given-names></name>
<name><surname>Tariq</surname><given-names>M.H.</given-names></name>
<name><surname>Cheng</surname><given-names>L.T.</given-names></name>
<name><surname>Chung</surname><given-names>Y.C.</given-names></name>
</person-group><article-title>Advancing PEDV Vaccination: Comparison between Inactivated and Flagellin N-Terminus-Adjuvanted Subunit Vaccines</article-title><source>Vaccines</source><year>2024</year><volume>12</volume><elocation-id>139</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines12020139</pub-id><pub-id pub-id-type="pmid">38400123</pub-id>
</element-citation></ref><ref id="B18-vetsci-12-00181"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reed</surname><given-names>L.J.</given-names></name>
<name><surname>Muench</surname><given-names>H.</given-names></name>
</person-group><article-title>A Simple Method of Estimating Fifty Per Cent Endpoints</article-title><source>Am. J. Epidemiol.</source><year>1938</year><volume>27</volume><fpage>493</fpage><lpage>497</lpage><pub-id pub-id-type="doi">10.1093/oxfordjournals.aje.a118408</pub-id></element-citation></ref><ref id="B19-vetsci-12-00181"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nigatu</surname><given-names>T.A.</given-names></name>
<name><surname>Afework</surname><given-names>M.</given-names></name>
<name><surname>Urga</surname><given-names>K.</given-names></name>
<name><surname>Ergete</surname><given-names>W.</given-names></name>
<name><surname>Makonnen</surname><given-names>E.</given-names></name>
</person-group><article-title>Toxicological investigation of acute and chronic treatment with Gnidia stenophylla Gilg root extract on some blood parameters and histopathology of spleen, liver and kidney in mice</article-title><source>BMC Res. Notes</source><year>2017</year><volume>10</volume><elocation-id>625</elocation-id><pub-id pub-id-type="doi">10.1186/s13104-017-2964-3</pub-id><pub-id pub-id-type="pmid">29183389</pub-id>
</element-citation></ref><ref id="B20-vetsci-12-00181"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hoa</surname><given-names>N.T.</given-names></name>
<name><surname>Afzal</surname><given-names>H.</given-names></name>
<name><surname>Gundegmaa</surname><given-names>U.</given-names></name>
<name><surname>Raadan</surname><given-names>O.</given-names></name>
<name><surname>Cheng</surname><given-names>L.T.</given-names></name>
<name><surname>Chu</surname><given-names>C.Y.</given-names></name>
<name><surname>Doan</surname><given-names>T.D.</given-names></name>
<name><surname>Chung</surname><given-names>Y.C.</given-names></name>
</person-group><article-title>Enhanced immune response with baculovirus-expressed BoHV-1 glycoprotein D in vaccine development</article-title><source>Vet. J.</source><year>2024</year><volume>308</volume><fpage>106228</fpage><pub-id pub-id-type="doi">10.1016/j.tvjl.2024.106228</pub-id><pub-id pub-id-type="pmid">39243806</pub-id>
</element-citation></ref><ref id="B21-vetsci-12-00181"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Serradell</surname><given-names>M.C.</given-names></name>
<name><surname>Rupil</surname><given-names>L.L.</given-names></name>
<name><surname>Martino</surname><given-names>R.A.</given-names></name>
<name><surname>Prucca</surname><given-names>C.G.</given-names></name>
<name><surname>Carranza</surname><given-names>P.G.</given-names></name>
<name><surname>Saura</surname><given-names>A.</given-names></name>
<name><surname>Fernandez</surname><given-names>E.A.</given-names></name>
<name><surname>Gargantini</surname><given-names>P.R.</given-names></name>
<name><surname>Tenaglia</surname><given-names>A.H.</given-names></name>
<name><surname>Petiti</surname><given-names>J.P.</given-names></name>
<etal/>
</person-group><article-title>Efficient oral vaccination by bioengineering virus-like particles with protozoan surface proteins</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>361</fpage><pub-id pub-id-type="doi">10.1038/s41467-018-08265-9</pub-id><pub-id pub-id-type="pmid">30664644</pub-id>
</element-citation></ref><ref id="B22-vetsci-12-00181"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zipperer</surname><given-names>A.</given-names></name>
<name><surname>Scheurer</surname><given-names>J.</given-names></name>
<name><surname>Kretschmer</surname><given-names>D.</given-names></name>
</person-group><article-title>Cytotoxicity Assays as Predictors of the Safety and Efficacy of Antimicrobial Agents</article-title><source>Methods Mol. Biol.</source><year>2023</year><volume>2601</volume><fpage>153</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-2855-3_8</pub-id><pub-id pub-id-type="pmid">36445583</pub-id>
</element-citation></ref><ref id="B23-vetsci-12-00181"><label>23.</label><element-citation publication-type="book"><person-group person-group-type="author">
<collab>ISO</collab>
</person-group><article-title>Biological evaluation of medical devices</article-title><source>Part 5: Tests for In Vitro Cytotoxicity</source><publisher-name>ISO</publisher-name><publisher-loc>Geneva, Switzerland</publisher-loc><year>2009</year><fpage>42</fpage></element-citation></ref><ref id="B24-vetsci-12-00181"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Boyaka</surname><given-names>P.N.</given-names></name>
</person-group><article-title>Inducing Mucosal IgA: A Challenge for Vaccine Adjuvants and Delivery Systems</article-title><source>J. Immunol.</source><year>2017</year><volume>199</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1601775</pub-id><pub-id pub-id-type="pmid">28630108</pub-id>
</element-citation></ref><ref id="B25-vetsci-12-00181"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wong</surname><given-names>P.T.</given-names></name>
<name><surname>Leroueil</surname><given-names>P.R.</given-names></name>
<name><surname>Smith</surname><given-names>D.M.</given-names></name>
<name><surname>Ciotti</surname><given-names>S.</given-names></name>
<name><surname>Bielinska</surname><given-names>A.U.</given-names></name>
<name><surname>Janczak</surname><given-names>K.W.</given-names></name>
<name><surname>Mullen</surname><given-names>C.H.</given-names></name>
<name><surname>Groom</surname><given-names>J.V.</given-names><suffix>2nd</suffix></name>
<name><surname>Taylor</surname><given-names>E.M.</given-names></name>
<name><surname>Passmore</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Formulation, high throughput in vitro screening and in vivo functional characterization of nanoemulsion-based intranasal vaccine adjuvants</article-title><source>PLoS ONE</source><year>2015</year><volume>10</volume><elocation-id>e0126120</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0126120</pub-id><pub-id pub-id-type="pmid">25962136</pub-id>
</element-citation></ref><ref id="B26-vetsci-12-00181"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kawai</surname><given-names>T.</given-names></name>
<name><surname>Akira</surname><given-names>S.</given-names></name>
</person-group><article-title>The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors</article-title><source>Nat. Immunol.</source><year>2010</year><volume>11</volume><fpage>373</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/ni.1863</pub-id><pub-id pub-id-type="pmid">20404851</pub-id>
</element-citation></ref><ref id="B27-vetsci-12-00181"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Miret</surname><given-names>S.</given-names></name>
<name><surname>Abrahamse</surname><given-names>L.</given-names></name>
<name><surname>de Groene</surname><given-names>E.M.</given-names></name>
</person-group><article-title>Comparison of in vitro models for the prediction of compound absorption across the human intestinal mucosa</article-title><source>J. Biomol. Screen.</source><year>2004</year><volume>9</volume><fpage>598</fpage><lpage>606</lpage><pub-id pub-id-type="doi">10.1177/1087057104267162</pub-id><pub-id pub-id-type="pmid">15475479</pub-id>
</element-citation></ref><ref id="B28-vetsci-12-00181"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jiang</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>F.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Zhang</surname><given-names>L.</given-names></name>
<name><surname>Lu</surname><given-names>C.</given-names></name>
<name><surname>Zheng</surname><given-names>L.</given-names></name>
<name><surname>Yan</surname><given-names>M.</given-names></name>
</person-group><article-title>Transcriptome analysis of PK-15 cells in innate immune response to porcine deltacoronavirus infection</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><elocation-id>e0223177</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0223177</pub-id><pub-id pub-id-type="pmid">31574122</pub-id>
</element-citation></ref><ref id="B29-vetsci-12-00181"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Licciardi</surname><given-names>P.V.</given-names></name>
<name><surname>Underwood</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Plant-derived medicines: A novel class of immunological adjuvants</article-title><source>Int. Immunopharmacol.</source><year>2011</year><volume>11</volume><fpage>390</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1016/j.intimp.2010.10.014</pub-id><pub-id pub-id-type="pmid">21056709</pub-id>
</element-citation></ref><ref id="B30-vetsci-12-00181"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhaskaran</surname><given-names>N.</given-names></name>
<name><surname>Shukla</surname><given-names>S.</given-names></name>
<name><surname>Srivastava</surname><given-names>J.K.</given-names></name>
<name><surname>Gupta</surname><given-names>S.</given-names></name>
</person-group><article-title>Chamomile: An anti-inflammatory agent inhibits inducible nitric oxide synthase expression by blocking RelA/p65 activity</article-title><source>Int. J. Mol. Med.</source><year>2010</year><volume>26</volume><fpage>935</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.3892/ijmm_00000545</pub-id><pub-id pub-id-type="pmid">21042790</pub-id>
</element-citation></ref><ref id="B31-vetsci-12-00181"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cvetanovi&#x00107;</surname><given-names>A.</given-names></name>
<name><surname>&#x00160;varc-Gaji&#x00107;</surname><given-names>J.</given-names></name>
<name><surname>Ma&#x00161;kovi&#x00107;</surname><given-names>P.</given-names></name>
<name><surname>Savi&#x00107;</surname><given-names>S.</given-names></name>
<name><surname>Nikoli&#x00107;</surname><given-names>L.</given-names></name>
</person-group><article-title>Antioxidant and biological activity of chamomile extracts obtained by different techniques: Perspective of using superheated water for isolation of biologically active compounds</article-title><source>Ind. Crops Prod.</source><year>2015</year><volume>65</volume><fpage>582</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1016/j.indcrop.2014.09.044</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="vetsci-12-00181-f001"><label>Figure 1</label><caption><p>The concept of PK-15 reporter cell line based on NF-&#x003ba;B activation screening. (<bold>A</bold>) Schematic of transfected plasmid pHAGE-NF-&#x003ba;B-luc-GFP (Plasmid #49343). (<bold>B</bold>) The workflow for the screening of plant extracts using NF-&#x003ba;B driven luciferase assay, toxicity, and immune efficacy analyses.</p></caption><graphic xlink:href="vetsci-12-00181-g001" position="float"/></fig><fig position="float" id="vetsci-12-00181-f002"><label>Figure 2</label><caption><p>Morphology and fluorescence percentages of PK15-KBR cells. (<bold>A</bold>) The morphology of PK-15 cells without transduction by lenti-NF-&#x003ba;B-luc-GFP was captured using light and fluorescence microscopes at 10&#x000d7; magnification. (<bold>B</bold>) The morphology of transduced PK-15 cells that were GFP-positive was captured using light and fluorescence microscopes at 10&#x000d7; magnification. (<bold>C</bold>) The morphology of the sorted GFP-positive cells was captured using light and fluorescence microscopes at 10&#x000d7; magnification. (<bold>D</bold>) The percentages of GFP-positive PK-15 cells were measured using flow cytometry analysis at different time points. *** indicates significant differences (<italic toggle="yes">p</italic> &#x02264; 0.001), ns indicates non-significant.</p></caption><graphic xlink:href="vetsci-12-00181-g002" position="float"/></fig><fig position="float" id="vetsci-12-00181-f003"><label>Figure 3</label><caption><p>NF-&#x01d0b;B quantification of transduced PK15-KBR cells after stimulation with a series of TNF-&#x003b1; concentrations. Dose&#x02013;response analysis of NF-&#x01d0b;B activity was measured using luminescence production via Luciferase assay system. (<bold>A</bold>) The fold-change of NF-&#x01d0b;B activity in PK15-KBR cells exposed to varying concentrations of TNF-&#x003b1; (ng/mL). (<bold>B</bold>) The fold-change of NF-&#x01d0b;B activity in PK15-KBR cells exposed to different conditions (cell numbers, drug action time, and concentration of solvent control). (<bold>C</bold>) The fold-change of NF-&#x01d0b;B activity in PK15-KBR cells exposed to varying concentrations of TNF-&#x003b1; (ng/mL) with addition of 1% DMSO as solvent control. The statistical analysis used in this study is detailed in <xref rid="sec2dot11-vetsci-12-00181" ref-type="sec">Section 2.11</xref>. Significant differences are as follows: <italic toggle="yes">p</italic> &#x02264; 0.05 (*), <italic toggle="yes">p</italic> &#x02264; 0.01 (**), <italic toggle="yes">p</italic> &#x02264; 0.001 (***).</p></caption><graphic xlink:href="vetsci-12-00181-g003" position="float"/></fig><fig position="float" id="vetsci-12-00181-f004"><label>Figure 4</label><caption><p>NF-&#x01d0b;B quantification of transduced PK15-KBR cells after stimulation with plant extracts. (<bold>A</bold>) The fold-change of NF-&#x01d0b;B activity in PK15-KBR cells exposed to plant extracts at a concentration of 10 &#x003bc;g/mL. DMSO (0.1%) was defined as solvent control and TNF-&#x003b1; (10 ng/mL as positive control. (<bold>B</bold>) The fold-change of NF-&#x01d0b;B activity in PK15-KBR cells exposed to varying concentrations of three extracts: chamomile, <italic toggle="yes">Boerhaavia diffusa</italic>, and mulberry. The statistical analysis used in this study is detailed in <xref rid="sec2dot11-vetsci-12-00181" ref-type="sec">Section 2.11</xref>. Significant differences are as follows: <italic toggle="yes">p</italic> &#x02264; 0.05 (*), <italic toggle="yes">p</italic> &#x02264; 0.001 (***), ns (non-significant).</p></caption><graphic xlink:href="vetsci-12-00181-g004" position="float"/></fig><fig position="float" id="vetsci-12-00181-f005"><label>Figure 5</label><caption><p>Cytotoxicity assay. CCK-8 assays were conducted to measure the cytotoxicity effects of PEs in PK-15 cells. The statistical analysis used in this study is detailed in <xref rid="sec2dot11-vetsci-12-00181" ref-type="sec">Section 2.11</xref>. Significant differences are as follows: <italic toggle="yes">p</italic> &#x02264; 0.05 (*), <italic toggle="yes">p</italic> &#x02264; 0.001 (***).</p></caption><graphic xlink:href="vetsci-12-00181-g005" position="float"/></fig><fig position="float" id="vetsci-12-00181-f006"><label>Figure 6</label><caption><p>Safety test of intramuscular injection in mice. (<bold>A</bold>) Experimental design for mice study. (<bold>B</bold>) Observation of the injection site 7 days after the injection of each group of vaccines. The point of arrow is the point of injection.</p></caption><graphic xlink:href="vetsci-12-00181-g006" position="float"/></fig><fig position="float" id="vetsci-12-00181-f007"><label>Figure 7</label><caption><p>Serum IgG antibody level in mice vaccinated with in-house inactivated PEDV and chamomile extracts. Indirect ELISA assays were conducted to measure serum antibody titer using in-house inactivated PEDV as the antigen. (<bold>A</bold>) Experimental schedule. (<bold>B</bold>) Serum IgG antibody level in mice intramuscularly injected with different doses of chamomile extracts: IM (0 mg/kg bw), IM 120 (6 mg/kg bw), IM 480 (24 mg/kg bw), and PBS as the control group. (<bold>C</bold>) Serum IgG antibody level in mice orally fed with different doses of chamomile extracts: OR (0 mg/kg bw), OR 120 (6 mg/kg bw), OR 480 (24 mg/kg bw), and PBS as the control group. The statistical analysis used in this study is detailed in <xref rid="sec2dot11-vetsci-12-00181" ref-type="sec">Section 2.11</xref>. Significant differences are as follows: <italic toggle="yes">p</italic> &#x02264; 0.05 (*), <italic toggle="yes">p</italic> &#x02264; 0.01(**), <italic toggle="yes">p</italic> &#x02264; 0.001 (***), <italic toggle="yes">p</italic> &#x02264; 0.0001 (****) and ns (non-significant).</p></caption><graphic xlink:href="vetsci-12-00181-g007" position="float"/></fig><fig position="float" id="vetsci-12-00181-f008"><label>Figure 8</label><caption><p>Intestinal IgA antibody level in mice vaccinated with in-house inactivated PEDV and chamomile extracts. Indirect ELISA assays were conducted to measure IgA antibody titer using in-house inactivated PEDV as coating antigen. The statistical analysis used in this study is detailed in <xref rid="sec2dot11-vetsci-12-00181" ref-type="sec">Section 2.11</xref>.</p></caption><graphic xlink:href="vetsci-12-00181-g008" position="float"/></fig><table-wrap position="float" id="vetsci-12-00181-t001"><object-id pub-id-type="pii">vetsci-12-00181-t001_Table 1</object-id><label>Table 1</label><caption><p>Toxicity test with PEs for mice study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Group</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose of Vaccine *</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N **</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PBS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chamomile&#x02014;Low</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 mg/kg bw</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Chamomile&#x02014;High</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 mg/kg bw</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mulberry&#x02014;Low</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 mg/kg bw</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mulberry&#x02014;High</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 mg/kg bw</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr></tbody></table><table-wrap-foot><fn><p>* Each mouse received a single dose of 0.1 mL vaccine via intramuscular injection on day 0. ** Number of mice used each group.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="vetsci-12-00181-t002"><object-id pub-id-type="pii">vetsci-12-00181-t002_Table 2</object-id><label>Table 2</label><caption><p>Vaccination experiments for mice study.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Group</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Dose of Vaccine *</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">N **</th></tr></thead><tbody><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">A. Intramuscular injection</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PBS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> TCID<sub>50</sub> (PEDV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IM 120</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> TCID<sub>50</sub> (PEDV) + 6 mg/kg bw (chamomile)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IM 480</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> TCID<sub>50</sub> (PEDV) + 24 mg/kg bw (chamomile)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">B. Oral administration</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PBS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> TCID<sub>50</sub> (PEDV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OR 120</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> TCID<sub>50</sub> (PEDV) + 6 mg/kg bw (chamomile)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">OR 480</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> TCID<sub>50</sub> (PEDV) + 24 mg/kg bw (chamomile)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5</td></tr></tbody></table><table-wrap-foot><fn><p>* For injection, each mouse received two doses (0.1 mL per dose) at an interval of 14 days. For oral administration, each mouse received four doses (0.1 mL per dose) every 7 days. ** Number of mice used each group.</p></fn></table-wrap-foot></table-wrap></floats-group></article>